Empagliflozin and Type 1 Diabetes: What People With T1D Should Know

Empagliflozin is a medication that belongs to a class of drugs called SGLT-2 inhibitors. It works by helping the kidneys remove extra glucose through urine, rather than relying on insulin to move glucose into cells. This mechanism of action is quite different from insulin therapy.

In Type 2 diabetes, where the body produces insulin but doesn't use it effectively, empagliflozin can be an effective treatment—either on its own or combined with other medications. It has also been shown to have benefits beyond blood sugar control, including protecting the heart and kidneys.

Although empagliflozin can technically improve blood sugar control in Type 1 diabetes when used alongside insulin, medical evidence does not support its use in this population. The key concern is an increased risk of diabetic ketoacidosis (DKA).

DKA is a serious condition where the body produces too many ketones, making the blood too acidic. It requires immediate medical attention and can be life-threatening. Because of this elevated risk, empagliflozin is not recommended for people with Type 1 diabetes, even if it seems to lower blood sugar numbers.

If you have Type 1 diabetes and your doctor is considering any new medication, it's important to discuss why empagliflozin would not be an appropriate choice and what safer alternatives might work for your situation.

The decision to use or avoid a medication should always be based on the best available safety evidence. For Type 1 diabetes, that evidence clearly shows empagliflozin carries unacceptable risks despite any short-term blood sugar benefits.

Your Type 1 diabetes treatment plan should focus on therapies that have been tested and proven safe for your condition—primarily insulin, along with other supportive strategies like continuous glucose monitoring, regular activity, and medical nutrition therapy. Your healthcare team can help you find the right combination for your individual needs.

Source: Diabetology & metabolic syndrome. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.